Aspreva delists from two exchanges following acquisition by Galenica

By Lisa Kerner

Charlotte, N.C., Jan. 3 - The plan of arrangement between Aspreva Pharmaceuticals Corp. and Galenica Group has been completed.

Under the plan, Galenica, through a wholly owned Canadian subsidiary, acquired all outstanding shares of Aspreva for $26 cash per share in a deal valued at $915 million, according to a company news release.

Aspreva delisted its shares from the Nasdaq on Thursday and will delist them from the Toronto Stock Exchange on Monday.

Zurich-based Galenica develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical services and access to databases and sets up networks.

Aspreva is a pharmaceutical company based in Victoria, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.